A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Phase 1

Suspended

• Conditions: Lymphoma, T-Cell, Peripheral; Mycosis Fungoides; Cell Therapy; Lymphoma, T-Cell, Cutaneous; Adoptive Cellular Immunotherapy
• Interventions: Other: MT-101 + Conditioning (Lymphodepleting) Chemotherapy; Biological: MT-101

• Registration Number: NCT05138458
• Lead Sponsor: Myeloid Therapeutics

Brief Summary

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.

Detailed Description

The research study is divided into two parts. The first part will be to determine the safety and tolerability of the study drug product. During this part of the study, there will be 4 groups of study patients. The first group of patients will receive a low dose of cells, the second group will receive the low dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood, the third group will receive a higher dose of cells, and the fourth group will receive the higher dose of cells and lymphodepleting chemotherapy to reduce the number of T cells in the blood. In the second part of the study, cells with or without chemotherapy will be administered based on results of Part 1 and the safety, tolerability, and efficacy of MT-101 will be assessed. All patient groups will receive 6 doses of drug product over 3 weeks.

Study Timeline

• Study First Submitted: 2021-11-16
• Study First Submitted QC: 2021-11-18
• Study First Posted: 2021-12-01
• Study Start: 2021-12-15
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-09
• Last Update Posted: 2023-11-13
• Primary Completion: 2024-11
• Study Completion: 2025-10

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Adults age > or equal to18 at the time the Informed Consent is signed
• Refractory or relapsed pathologically confirmed T Cell Lymphoma (TCL): Peripheral T cell Lymphoma not otherwise specified (PTCL-NOS) , Angioimmunoblastic T cell Lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALCL), ALK-positive ALCL, or Mycosis Fungoides (MF) stage IIB-IV including large cell transformation
• CD5-expressing tumor by IHC or flow cytometry of tumor biopsy within 3 months of Screening or at Screening
• Eastern Cooperative Oncology Group performance status < 2
• Adequate organ function as defined in the protocol.

Key

Exclusion Criteria

• B1 and B2 disease (as defined in protocol for subjects with MF)
• Known central nervous system involvement by PTCL
• History of allogeneic transplant
• History of intolerance to leukapheresis, plasmapheresis, or blood donation
• Pregnant or nursing women
• Any acute illness including fever (> 100.4°F or > 38°C), except fever related to tumor
• Active systemic bacterial, fungal, or viral infection
• Active chronic infection
• Other primary malignancies, except adequately treated malignancies or complete remission
• Active autoimmune disease that has required systemic therapy in the last 2 years
• History of hemophagocytic lymphohistiocytosis
• History of severe, immediate hypersensitivity reaction attributed to penicillin
• Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 2 and Cohort 4	MT-101 + Conditioning (Lymphodepleting) Chemotherapy	MT-101 preceded by conditioning (lymphodepleting) chemotherapy
Cohort 1 and Cohort 3	MT-101	MT-101

Primary Outcome Measures

Name	Time	Method
Safety and Tolerability of MT-101	4 weeks	Safety and tolerability of the drug will be determined based on observed adverse events (AEs), including all potential dose limiting toxicities.

Secondary Outcome Measures

Name	Time	Method
MT-101 cell kinetics in blood	4 weeks	The quantity of MT-101 RNA in the blood.
The objective response rate	24 weeks	The ORR is defined as the number (%) of subjects achieving a best overall response of complete response (CR) or partial response (PR)

Trial Locations

Locations (6)

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Dana-Farber/Mass General Brigham Cancer Care; 🇺🇸 Boston, Massachusetts, United States

Colorado Blood Cancer Institute; 🇺🇸 Denver, Colorado, United States

City of Hope Comprehensive Cancer Center; 🇺🇸 Duarte, California, United States

University of Virginia Comprehensive Cancer Center; 🇺🇸 Charlottesville, Virginia, United States

Thomas Jefferson University; 🇺🇸 Philadelphia, Pennsylvania, United States